Екатерина Вадимовна Евдокимова
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Екатерина Вадимовна Евдокимова has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Yaroslav A. Zhulikov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
11 shared publications - Alla A. Markovich
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
8 shared publications - Elena V. Artamonova
N.N. Blokhin National Medical Investigation Centre of Oncology; N.I. Pirogov Russian National Research Medical University (Pirogov University); M.F. Vladimirsky Moscow Regional Research Clinical Institute
8 shared publications - Elena I. Kovalenko
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
6 shared publications - Elena V. Kaytukova
Pediatrics and Child Health Research Institute in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical University
5 shared publications - Ivan S. Stilidi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Alfmed LLC in Medical alphabet
- No. 15,p. 17-21
Assessment of somatostatin receptor expression in patients with pulmonary and thymic neuroendocrine neoplasms. First results of a single-center study
Background . Pulmonary and thymic neuroendocrine neoplasms (NENs) are divided into a group of well-differentiated neuroendocrine tumors (NETs), including typical and atypical carcinoids (TC and AC), and a group of poorly differentiated neuroendocrine carcinomas (NECs), including large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). According to the 2022 WHO classification of thoracic NENs, AC are subdivided into two groups: AC with a low mitotic index (MI) (AC G2) and AC with an elevated MI (AC G3). Russian experts distinguish well-differentiated pulmonary and thymic neuroendocrine tumors (NETs), including TC (analogous to gastrointestinal NET G1), AC with Ki‑6730% (AC G3) (by analogy with gastrointestinal NET G2 and G3), and neuroendocrine carcinomas (LCNEC and SCLC). Data on the expression of somatostatin receptors (SSTR) subtypes 2 and 5 in thoracic NENs remain limited. Aim . To compare the expression of SSTR2A and SSTR5 using immunohistochemistry (IHC) and 68Ga-DOTATATE PET/CT. Materials and methods . The study included 173 patients with thoracic NENs. SSTR status was determined in 133 cases (76.9%): by IHC in 65.4% (n=87) and by 68Ga-DOTATATE PET/CT in 62.4% (n=83). Results . In the TC subgroup, SSTR positivity by IHC was detected in 66.7% of cases; in AC G2–46.5%, AC G3–70%, and LCNEC – 38.5%. SSTR2A expression was the most frequently observed. Using 68Ga-DOTATATE PET/CT, SSTR positivity was detected in 82.4% of TC cases, 86% of AC G2, 100% of AC G3, and 100% of LCNEC. The discordance rate between IHC and PET/CT was 41.7% (p=0.074). Overall survival decreased with increasing Ki‑67 (pConclusions . 68Ga-DOTATATE PET/CT demonstrates higher sensitivity for detecting SSTR expression, however, IHC may identify additional isolated IHC-positive cases.
- 1 October 2026
- Published by Alfmed LLC in Medical alphabet
- No. 15,p. 17-21
Open AccessAssessment of somatostatin receptor expression in patients with pulmonary and thymic neuroendocrine neoplasms. First results of a single-center study
Background . Pulmonary and thymic neuroendocrine neoplasms (NENs) are divided into a group of well-differentiated neuroendocrine tumors (NETs), including typical and atypical carcinoids (TC and AC), and a group of poorly differentiated neuroendocrine carcinomas (NECs), including large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). According to the 2022 WHO classification of thoracic NENs, AC are subdivided into two groups: AC with a low mitotic index (MI) (AC G2) and AC with an elevated MI (AC G3). Russian experts distinguish well-differentiated pulmonary and thymic neuroendocrine tumors (NETs), including TC (analogous to gastrointestinal NET G1), AC with Ki‑6730% (AC G3) (by analogy with gastrointestinal NET G2 and G3), and neuroendocrine carcinomas (LCNEC and SCLC). Data on the expression of somatostatin receptors (SSTR) subtypes 2 and 5 in thoracic NENs remain limited. Aim . To compare the expression of SSTR2A and SSTR5 using immunohistochemistry (IHC) and 68Ga-DOTATATE PET/CT. Materials and methods . The study included 173 patients with thoracic NENs. SSTR status was determined in 133 cases (76.9%): by IHC in 65.4% (n=87) and by 68Ga-DOTATATE PET/CT in 62.4% (n=83). Results . In the TC subgroup, SSTR positivity by IHC was detected in 66.7% of cases; in AC G2–46.5%, AC G3–70%, and LCNEC – 38.5%. SSTR2A expression was the most frequently observed. Using 68Ga-DOTATATE PET/CT, SSTR positivity was detected in 82.4% of TC cases, 86% of AC G2, 100% of AC G3, and 100% of LCNEC. The discordance rate between IHC and PET/CT was 41.7% (p=0.074). Overall survival decreased with increasing Ki‑67 (pConclusions . 68Ga-DOTATATE PET/CT demonstrates higher sensitivity for detecting SSTR expression, however, IHC may identify additional isolated IHC-positive cases.
- Open Access
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 35-44
Retrospective analysis of BUCEN score prognostic value in Russian population of patients with advanced adrenocortical carcinoma treated with platinum-based chemotherapy in combination with mitotane
Introduction. Currently, the algorithm for selecting first-line treatment for advanced adrenocortical carcinoma (ACC) is not clearly defined; the choice between mitotane monotherapy and its combination with platinum-based chemotherapy remains controversial. In a large retrospective study (n = 439), the BUCEN scoring system was proposed as a predictor of treatment response, which could help determine first-line therapy [9]. Our study aimed to evaluate the prognostic value of the BUCEN scores in the Russian population of patients with advanced ACC, treated with a combination of platinum-based chemotherapy and mitotane. Materials and Methods. This retrospective single-center study included patients aged ≥ 18 years with advanced ACC and pre-assessed BUCEN scores who received platinum-based chemotherapy in combination with mitotane at the N. N. Blokhin National Medical Research Center of Oncology between 2016 and 2025. Result. The study included 63 patients with BUCEN scores of 0–2 (n = 31; 49.2 %) and ≥ 3 (n = 32; 50.8 %). Fifty patients (79.4 %) received etoposide + cisplatin + doxorubicin (EDP), 5 patients (7.9 %) received etoposide + cisplatin (EP), and 8 (12.7 %) received etoposide + carboplatin (EC). Therapeutic serum levels of mitotane were achieved in 42 patients (66.7 %). The objective response rate (ORR), disease control rate (DCR) at ≥ 6 months, and DCR at ≥ 12 months were 20.6 %, 62.3 %, and 26.3 %, respectively. A BUCEN score of 0–2 was associated with an improved ORR (p = 0.03), a DCR at ≥ 6 months (p < 0.01), and a DCR at ≥ 12 months (p = 0.03). A multivariate analysis revealed that non-anthracycline regimens in patients with BUCEN ≥ 3 were associated with a statistically significant decrease in progression-free survival (PFS) and overall survival (OS). A statistically significant OS improvement was observed in patients with recurrence-free survival of ≥ 12 months post-adrenalectomy (p = 0.04). Conclusion. The BUCEN scoring system is reproducible, simple to use, and could be applied for the stratification of patients with advanced ACC. Implementation of this system in clinical practice to pre-select patients for mitotane monotherapy as a first-line treatment requires prospective validation. The significantly poorer outcomes in the EP / EC group may partly reflect patient characteristics, as these regimens were used in those with contraindications to anthracyclines or cisplatin. However, based on our data, we do not recommend non-anthracycline regimens in patients without contraindications to EDP chemotherapy.
- 28 August 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (2) , 35-44
Open AccessRetrospective analysis of BUCEN score prognostic value in Russian population of patients with advanced adrenocortical carcinoma treated with platinum-based chemotherapy in combination with mitotane
Introduction. Currently, the algorithm for selecting first-line treatment for advanced adrenocortical carcinoma (ACC) is not clearly defined; the choice between mitotane monotherapy and its combination with platinum-based chemotherapy remains controversial. In a large retrospective study (n = 439), the BUCEN scoring system was proposed as a predictor of treatment response, which could help determine first-line therapy [9]. Our study aimed to evaluate the prognostic value of the BUCEN scores in the Russian population of patients with advanced ACC, treated with a combination of platinum-based chemotherapy and mitotane. Materials and Methods. This retrospective single-center study included patients aged ≥ 18 years with advanced ACC and pre-assessed BUCEN scores who received platinum-based chemotherapy in combination with mitotane at the N. N. Blokhin National Medical Research Center of Oncology between 2016 and 2025. Result. The study included 63 patients with BUCEN scores of 0–2 (n = 31; 49.2 %) and ≥ 3 (n = 32; 50.8 %). Fifty patients (79.4 %) received etoposide + cisplatin + doxorubicin (EDP), 5 patients (7.9 %) received etoposide + cisplatin (EP), and 8 (12.7 %) received etoposide + carboplatin (EC). Therapeutic serum levels of mitotane were achieved in 42 patients (66.7 %). The objective response rate (ORR), disease control rate (DCR) at ≥ 6 months, and DCR at ≥ 12 months were 20.6 %, 62.3 %, and 26.3 %, respectively. A BUCEN score of 0–2 was associated with an improved ORR (p = 0.03), a DCR at ≥ 6 months (p < 0.01), and a DCR at ≥ 12 months (p = 0.03). A multivariate analysis revealed that non-anthracycline regimens in patients with BUCEN ≥ 3 were associated with a statistically significant decrease in progression-free survival (PFS) and overall survival (OS). A statistically significant OS improvement was observed in patients with recurrence-free survival of ≥ 12 months post-adrenalectomy (p = 0.04). Conclusion. The BUCEN scoring system is reproducible, simple to use, and could be applied for the stratification of patients with advanced ACC. Implementation of this system in clinical practice to pre-select patients for mitotane monotherapy as a first-line treatment requires prospective validation. The significantly poorer outcomes in the EP / EC group may partly reflect patient characteristics, as these regimens were used in those with contraindications to anthracyclines or cisplatin. However, based on our data, we do not recommend non-anthracycline regimens in patients without contraindications to EDP chemotherapy.
- Open Access
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Retrospective non-comparative single-center study of platinum-based regimen efficacy in the 1st line therapy of high-grade neuroendocrine carcinomas of gynecologic tract
Introduction. Neuroendocrine carcinomas (NEC) of gynecologic tract are rare and aggressive tumors for which there are currently no standardized approaches to systemic therapy. Platinum-based chemotherapy regimens are the main treatment method, but data on their efficacy are limited to a few retrospective studies. Aim. To evaluate the efficacy of platinum-based chemotherapy as first-line treatment for patients with metastatic gynecologic NEC, as well as the prognostic role of tumor histology, tumor location, disease extent, frequency of second-line therapy, and progression-free survival (PFS). Materials and methods. A retrospective analysis was conducted of the efficacy of platinum-based chemotherapy as first-line therapy for primary metastatic or recurrent (with a platinum-free interval ≥12 months) NEC of gynecologic tract at the N. N. Blokhin National Medical Research Centre for Oncology in 2017–2024. Results. The most common site of primary tumor was the cervix (n = 18; 62.1 %), 5 patients had ovarian NEC (17.2 %), 3 had uterine NEC (10.3 %), 2 had vulvar NEC (6.9 %), and 1 case of vaginal NEC was diagnosed (3.4 %). In 15 patients (51.7 %), the disease was detected at stage IV, and in 14 (48.3 %), progression was noted after primary treatment with a platinum-free interval of ≥12 months. Small-cell histological type was detected in 17 patients (58.6 %), large-cell in 12 of 29 (41.4 %). The frequency of high microsatellite instability (MSI) cases was 13.3 % (2 out of 15 examined), and positive expression of somatostatin receptors 2 and / or 5 (SSTR) was found in 33.3 % (4 out of 12 examined). In most cases, etoposide + cisplatin / carboplatin regimens were used (n = 25; 86.2 %), and 4 patients (13.8 %) received the paclitaxel + carboplatin regimen. The objective response rate was 44.8 %; the median PFS was 7.5 months (95 % confidence interval (CI) 2.9–12.1), median overall survival (OS) was 14 months (95 % CI 13–16.2). Disease control ≥6 months was achieved in 15 (51.7 %) patients, ≥12 months in 6 (20.7 %). Peritoneal carcinomatosis was significantly associated with worse PFS (hazard ratio 4.37; p = 0.01), and ECOG status 1–2 was associated with worse OS (hazard ratio 3.4; p = 0.01). No statistically significant differences in survival were found between histological types. Conclusion. First-line platinum-based chemotherapy demonstrates efficacy comparable to previously published data in metastatic NEC of gynecologic tract. The high frequency of MSI-high cases justifies its routine measurement. The expression of somatostatin receptors is of interest for further study as a prognostic and therapeutic marker.
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Open AccessRetrospective non-comparative single-center study of platinum-based regimen efficacy in the 1st line therapy of high-grade neuroendocrine carcinomas of gynecologic tract
Introduction. Neuroendocrine carcinomas (NEC) of gynecologic tract are rare and aggressive tumors for which there are currently no standardized approaches to systemic therapy. Platinum-based chemotherapy regimens are the main treatment method, but data on their efficacy are limited to a few retrospective studies. Aim. To evaluate the efficacy of platinum-based chemotherapy as first-line treatment for patients with metastatic gynecologic NEC, as well as the prognostic role of tumor histology, tumor location, disease extent, frequency of second-line therapy, and progression-free survival (PFS). Materials and methods. A retrospective analysis was conducted of the efficacy of platinum-based chemotherapy as first-line therapy for primary metastatic or recurrent (with a platinum-free interval ≥12 months) NEC of gynecologic tract at the N. N. Blokhin National Medical Research Centre for Oncology in 2017–2024. Results. The most common site of primary tumor was the cervix (n = 18; 62.1 %), 5 patients had ovarian NEC (17.2 %), 3 had uterine NEC (10.3 %), 2 had vulvar NEC (6.9 %), and 1 case of vaginal NEC was diagnosed (3.4 %). In 15 patients (51.7 %), the disease was detected at stage IV, and in 14 (48.3 %), progression was noted after primary treatment with a platinum-free interval of ≥12 months. Small-cell histological type was detected in 17 patients (58.6 %), large-cell in 12 of 29 (41.4 %). The frequency of high microsatellite instability (MSI) cases was 13.3 % (2 out of 15 examined), and positive expression of somatostatin receptors 2 and / or 5 (SSTR) was found in 33.3 % (4 out of 12 examined). In most cases, etoposide + cisplatin / carboplatin regimens were used (n = 25; 86.2 %), and 4 patients (13.8 %) received the paclitaxel + carboplatin regimen. The objective response rate was 44.8 %; the median PFS was 7.5 months (95 % confidence interval (CI) 2.9–12.1), median overall survival (OS) was 14 months (95 % CI 13–16.2). Disease control ≥6 months was achieved in 15 (51.7 %) patients, ≥12 months in 6 (20.7 %). Peritoneal carcinomatosis was significantly associated with worse PFS (hazard ratio 4.37; p = 0.01), and ECOG status 1–2 was associated with worse OS (hazard ratio 3.4; p = 0.01). No statistically significant differences in survival were found between histological types. Conclusion. First-line platinum-based chemotherapy demonstrates efficacy comparable to previously published data in metastatic NEC of gynecologic tract. The high frequency of MSI-high cases justifies its routine measurement. The expression of somatostatin receptors is of interest for further study as a prognostic and therapeutic marker.
- Open Access
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Efficacy of mFOLFIRINOX chemotherapy for treatment of high-grade G3 neuroendocrine tumors and gastroenteropancreatic neuroendocrine carcinomas
Background. Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC) are rare tumors. Despite the differences in genetic characteristics, treatment principles for GEP-NECs are extrapolated from lung NECs. A small retrospective study demonstrated potential effectiveness of the mFOLFIRINOX regimen. Aim. To evaluate the efficacy of mFOLFIRINOX ± somatostatin analogues in treatment of inoperable or metastatic G3 Ki-67 ≥55 % GEP-NECs and neuroendocrine tumors (NETs) in a prospective cohort. Materials and methods. A prospective single-center phase II trial with the Simon’s two-stage design was conducted. The primary endpoint was disease control (DC) ≥6 months. The statistical hypothesis was that the mFOLFIRINOX regimen would increase the disease control rate from 50 % (historical control) to 70 %. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). In the 1st stage, 16 patients were planned for enrollment. If ≥9 patients achieved DC ≥6 months, the cohort would be expanded to 39 patients. Inclusion criteria: patients ≥18 years with histologically confirmed G3 Ki-67 ≥55 % GEP-NEC or NET, ECOG performance status 0–2. Patient enrollment took place between 2019 to February of 2024. Results. Sixteen patients were included in the study (12 men, 4 women). The most common primary tumor sites were the stomach (8 patients, 50 %) and pancreas (5 patients, 31.3 %). Large-cell NEC was diagnosed in 10 patients (62.5 %), small-cell NEC in 1 patient (6.3 %), and G3 NET in 5 patients (31.3 %). Median Ki-67 index was 70 % (range 40–95 %). Stage IV disease was diagnosed in 15 patients (93.7 %), and 1 patient (6.3 %) had unresectable gastric NEC. The liver was the most frequent site of metastases (n = 11, 68.8 %), with isolated liver involvement in 9 patients (56.3 %). ECOG performance status was 0–1 in 15 patients (93.7 %). The majority (n = 14, 87.5 %) of patients received mFOLFIRINOX as 1st line treatment. Positive expression of somatostatin receptors SSTR2A / 5 was found in 7 patients (43.7 %), who additionally received somatostatin analogues. ORR was 62.5 % (n = 10), and stable disease was observed in 37.5 % (n = 6) of patients. Disease control ≥6 months was achieved in 93.7 % of patients (n = 15). With a median follow-up of 13.2 months, median PFS was 10.8 months (95 % confidence interval 7.57–14.1). One serious adverse event (myocardial infarction) was reported. No grade V toxicity was observed. Conclusion. mFOLFIRINOX chemotherapy demonstrated promising results in treatment of G3 Ki-67 ≥55 % GEP NECs and NETs. The primary endpoint was met, and the study is ongoing.
- 15 March 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (1)
Open AccessEfficacy of mFOLFIRINOX chemotherapy for treatment of high-grade G3 neuroendocrine tumors and gastroenteropancreatic neuroendocrine carcinomas
Background. Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC) are rare tumors. Despite the differences in genetic characteristics, treatment principles for GEP-NECs are extrapolated from lung NECs. A small retrospective study demonstrated potential effectiveness of the mFOLFIRINOX regimen. Aim. To evaluate the efficacy of mFOLFIRINOX ± somatostatin analogues in treatment of inoperable or metastatic G3 Ki-67 ≥55 % GEP-NECs and neuroendocrine tumors (NETs) in a prospective cohort. Materials and methods. A prospective single-center phase II trial with the Simon’s two-stage design was conducted. The primary endpoint was disease control (DC) ≥6 months. The statistical hypothesis was that the mFOLFIRINOX regimen would increase the disease control rate from 50 % (historical control) to 70 %. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). In the 1st stage, 16 patients were planned for enrollment. If ≥9 patients achieved DC ≥6 months, the cohort would be expanded to 39 patients. Inclusion criteria: patients ≥18 years with histologically confirmed G3 Ki-67 ≥55 % GEP-NEC or NET, ECOG performance status 0–2. Patient enrollment took place between 2019 to February of 2024. Results. Sixteen patients were included in the study (12 men, 4 women). The most common primary tumor sites were the stomach (8 patients, 50 %) and pancreas (5 patients, 31.3 %). Large-cell NEC was diagnosed in 10 patients (62.5 %), small-cell NEC in 1 patient (6.3 %), and G3 NET in 5 patients (31.3 %). Median Ki-67 index was 70 % (range 40–95 %). Stage IV disease was diagnosed in 15 patients (93.7 %), and 1 patient (6.3 %) had unresectable gastric NEC. The liver was the most frequent site of metastases (n = 11, 68.8 %), with isolated liver involvement in 9 patients (56.3 %). ECOG performance status was 0–1 in 15 patients (93.7 %). The majority (n = 14, 87.5 %) of patients received mFOLFIRINOX as 1st line treatment. Positive expression of somatostatin receptors SSTR2A / 5 was found in 7 patients (43.7 %), who additionally received somatostatin analogues. ORR was 62.5 % (n = 10), and stable disease was observed in 37.5 % (n = 6) of patients. Disease control ≥6 months was achieved in 93.7 % of patients (n = 15). With a median follow-up of 13.2 months, median PFS was 10.8 months (95 % confidence interval 7.57–14.1). One serious adverse event (myocardial infarction) was reported. No grade V toxicity was observed. Conclusion. mFOLFIRINOX chemotherapy demonstrated promising results in treatment of G3 Ki-67 ≥55 % GEP NECs and NETs. The primary endpoint was met, and the study is ongoing.
- Open Access
- 11 March 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (1)
Prospective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer
Введение. Комбинация химиотерапии EDP (этопозида, доксорубицина, цисплатина) с митотаном является стандартом первой линии терапии адренокортикального рака (АКР). Достижение терапевтических концентраций митотана связано с улучшением выживаемости без прогрессирования (ВБП) и общей выживаемости (ОВ) в ряде исследований. В большинстве опубликованных работ схема назначения митотана определялась локальными протоколами, что подчеркивает необходимость валидации протокола по его назначению и создания унифицированного режима дозирования. Материалы и методы. Проведено одноцентровое проспективное исследование II фазы с использованием двухэтапного дизайна Симона. В исследование включали пациентов с местнораспространенным или метастатическим АКР, ECOG 0–1, ранее не получавших митотан. Первичная конечная точка — частота достижения терапевтической концентрации митотана (14–20 мкг/мл). Статистическая гипотеза предполагала увеличение частоты достижения терапевтической концентрации с 50 до 70 % (β = 0,2; α = 0,05). Вторичные конечные точки — частота объективного ответа и контроля болезни ≥ 6 мес, ВБП, ОВ, безопасность терапии. Митотан назначался в начальной дозе 2 г/сут с постепенной эскалацией каждые 3-5 дней на 0,5 г до 4 г/сут, с последующей коррекцией дозы в зависимости от его концентрации в крови. Все пациенты одновременно с митотаном получали стандартную платиносодержащую химиотерапию (EDP или EP/EC). Результаты. В исследование включено 47 пациентов: 27 мужчин (57,4 %) и 20 женщин (42,5 %). Все пациенты получали платиносодержащую химиотерапию — 45 (95,8 %) EDP, 2 — EP/EC. При медиане наблюдения 12,4 мес терапевтическая концентрация митотана достигнута в 72,3 % (n = 34) случаев, медиана времени до ее достижения — 4,3 мес (95 % ДИ 3,3–5,3 мес). Частота объективного ответа составила 29,7 % (n = 14), контроль заболевания ≥ 6 мес — 63,8 % (n = 30). Медиана ВБП — 8,4 мес (95 % ДИ 4,2–12,6), медиана ОВ — 24,6 мес (9,9–44,6). Профиль нежелательных явлений не отличался от ранее описанного. Выводы. Разработанный режим митотана обеспечивает быстрое и безопасное достижение терапевтической концентрации у большинства пациентов и может быть рекомендован для рутинной практики.
- 11 March 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (1)
Open AccessProspective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer
Введение. Комбинация химиотерапии EDP (этопозида, доксорубицина, цисплатина) с митотаном является стандартом первой линии терапии адренокортикального рака (АКР). Достижение терапевтических концентраций митотана связано с улучшением выживаемости без прогрессирования (ВБП) и общей выживаемости (ОВ) в ряде исследований. В большинстве опубликованных работ схема назначения митотана определялась локальными протоколами, что подчеркивает необходимость валидации протокола по его назначению и создания унифицированного режима дозирования. Материалы и методы. Проведено одноцентровое проспективное исследование II фазы с использованием двухэтапного дизайна Симона. В исследование включали пациентов с местнораспространенным или метастатическим АКР, ECOG 0–1, ранее не получавших митотан. Первичная конечная точка — частота достижения терапевтической концентрации митотана (14–20 мкг/мл). Статистическая гипотеза предполагала увеличение частоты достижения терапевтической концентрации с 50 до 70 % (β = 0,2; α = 0,05). Вторичные конечные точки — частота объективного ответа и контроля болезни ≥ 6 мес, ВБП, ОВ, безопасность терапии. Митотан назначался в начальной дозе 2 г/сут с постепенной эскалацией каждые 3-5 дней на 0,5 г до 4 г/сут, с последующей коррекцией дозы в зависимости от его концентрации в крови. Все пациенты одновременно с митотаном получали стандартную платиносодержащую химиотерапию (EDP или EP/EC). Результаты. В исследование включено 47 пациентов: 27 мужчин (57,4 %) и 20 женщин (42,5 %). Все пациенты получали платиносодержащую химиотерапию — 45 (95,8 %) EDP, 2 — EP/EC. При медиане наблюдения 12,4 мес терапевтическая концентрация митотана достигнута в 72,3 % (n = 34) случаев, медиана времени до ее достижения — 4,3 мес (95 % ДИ 3,3–5,3 мес). Частота объективного ответа составила 29,7 % (n = 14), контроль заболевания ≥ 6 мес — 63,8 % (n = 30). Медиана ВБП — 8,4 мес (95 % ДИ 4,2–12,6), медиана ОВ — 24,6 мес (9,9–44,6). Профиль нежелательных явлений не отличался от ранее описанного. Выводы. Разработанный режим митотана обеспечивает быстрое и безопасное достижение терапевтической концентрации у большинства пациентов и может быть рекомендован для рутинной практики.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 11-15
Efficacy of adjuvant therapy with somatostatin analogues in recurrent type I gastric neuroendocrine tumors
Introduction. Neuroendocrine gastric tumor (gNETs) type 1 associated with chronic autoimmune atrophic gastritis, hypergastrinemia and usually have multifocal lesions and high frequency of local recurrence (~70 % for 2 year). Somatostatin analogs (SA) showed promised data in neoadjuvant setting with 84 % of complete response in meta-analysis. The aim of this study was to evaluate efficacy adjuvant treatment with SA for recurrent gNETs type 1. Methods. This retrospective, single center study included patients (pts) with recurrent gNETs who received adjuvant treatment with SA. Recruitment of pts was carried from 2012 to February 2024. Results. The study included 35 pts, 33 females and 2 males. Endoscopic mucosal resection (EMR) was performed in 34 cases (97.1 %), gastric resection in 1 (2.9 %). The median of previous EMR was 2 (1–6). The most of pts have multifocal lesions – 28 (80 %), the median of lesions is 5. Tumor size >10 mm was observed at 2 cases (5.7 %), the median size – 6 mm. One pts had N+. The median of Ki67 was 3,5 % (1–10 %), 21 (60 %) pts have G2 tumors and 14 (40 %) – G1. All pts received adjuvant therapy with SA, 33 (94.3 %) long-active octreotide 30 mg and 2 (5.7 %) lanreotide 120 mg. The time of SA therapy was Conclusions. Adjuvant therapy with somatostatin analogs significantly reduced gastrin levels and improved disease-free survival, demonstrating their antiproliferative effect in type 1 gastric neuroendocrine tumors. However, given the favorable prognosis and low risk of regional or distant metastases, the role of these agents in the treatment of gastric NETs requires further clarification in prospective studies.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 14,p. 11-15
Efficacy of adjuvant therapy with somatostatin analogues in recurrent type I gastric neuroendocrine tumors
Introduction. Neuroendocrine gastric tumor (gNETs) type 1 associated with chronic autoimmune atrophic gastritis, hypergastrinemia and usually have multifocal lesions and high frequency of local recurrence (~70 % for 2 year). Somatostatin analogs (SA) showed promised data in neoadjuvant setting with 84 % of complete response in meta-analysis. The aim of this study was to evaluate efficacy adjuvant treatment with SA for recurrent gNETs type 1. Methods. This retrospective, single center study included patients (pts) with recurrent gNETs who received adjuvant treatment with SA. Recruitment of pts was carried from 2012 to February 2024. Results. The study included 35 pts, 33 females and 2 males. Endoscopic mucosal resection (EMR) was performed in 34 cases (97.1 %), gastric resection in 1 (2.9 %). The median of previous EMR was 2 (1–6). The most of pts have multifocal lesions – 28 (80 %), the median of lesions is 5. Tumor size >10 mm was observed at 2 cases (5.7 %), the median size – 6 mm. One pts had N+. The median of Ki67 was 3,5 % (1–10 %), 21 (60 %) pts have G2 tumors and 14 (40 %) – G1. All pts received adjuvant therapy with SA, 33 (94.3 %) long-active octreotide 30 mg and 2 (5.7 %) lanreotide 120 mg. The time of SA therapy was Conclusions. Adjuvant therapy with somatostatin analogs significantly reduced gastrin levels and improved disease-free survival, demonstrating their antiproliferative effect in type 1 gastric neuroendocrine tumors. However, given the favorable prognosis and low risk of regional or distant metastases, the role of these agents in the treatment of gastric NETs requires further clarification in prospective studies.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 49-54
Retrospective Analysis of the Effectiveness of Somatostatin Analogs in the Treatment of Metastatic Pheochromocytoma/Paraganglioma. A Clinical Case on the efficacy of long-acting release octreotide
Introduction. Pheochromocytoma (PC) and paraganglioma (PG) are neuroendocrine neoplasms and are characterized by a high frequency of somatostatin receptor (SSTR) expression. The efficacy of somatostatin analogues in PC/PG remains poorly studied, despite the lack of evidence base, these drugs are included in the international NCCN recommendations. The aim of this study was to investigate the effectiveness of somatostatin analogues in the treatment of PC/PG.Materials and methods. This retrospective single-center study included patients older than 18 years with positive expression of SSTR 2A и/или SSTR 5 or with accumulation of 68Ga-DOTATATE who received somatostatin analogs (octreotide-depo or lanreotide) at the first line of treatment for metastatic PC/PG from April 2020 to September 2023.Results. The study included 8 patients, 6 male (75 %) and 2 female (25 %). All patients had positive SSTR 2A expression and accumulation on 68Ga-DOTATATE PET. Half patients (N=4, 50 %) had pheochromocytoma and half (N=4, 50 %) paraganglioma. SDHB mutation was detected in 1 (12.5 %) patient. Four patients (50 %) had disease progression on follow-up before starting therapy with somatostatin analogues. No objective response was achieved (0 %). However, all patients had disease control ≥ 6 months. Two (33.3 %) of 6 had a ≥ 50 % decrease in metanephrine/ normetanephrine secretion. Median PFS was 21.57 months. (95 % Confidence Interval 14.95–28.19).Conclusion. Based on our findings, we recommend considering somatostatin analogs as a first-line treatment option for patients with indolent disease course and low tumor burden who demonstrate progression during active surveillance. The impact of long-acting somatostatin analogs on catecholamine secretion warrants further investigation in a prospective cohort.
- 3 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 11,p. 49-54
Retrospective Analysis of the Effectiveness of Somatostatin Analogs in the Treatment of Metastatic Pheochromocytoma/Paraganglioma. A Clinical Case on the efficacy of long-acting release octreotide
Introduction. Pheochromocytoma (PC) and paraganglioma (PG) are neuroendocrine neoplasms and are characterized by a high frequency of somatostatin receptor (SSTR) expression. The efficacy of somatostatin analogues in PC/PG remains poorly studied, despite the lack of evidence base, these drugs are included in the international NCCN recommendations. The aim of this study was to investigate the effectiveness of somatostatin analogues in the treatment of PC/PG.Materials and methods. This retrospective single-center study included patients older than 18 years with positive expression of SSTR 2A и/или SSTR 5 or with accumulation of 68Ga-DOTATATE who received somatostatin analogs (octreotide-depo or lanreotide) at the first line of treatment for metastatic PC/PG from April 2020 to September 2023.Results. The study included 8 patients, 6 male (75 %) and 2 female (25 %). All patients had positive SSTR 2A expression and accumulation on 68Ga-DOTATATE PET. Half patients (N=4, 50 %) had pheochromocytoma and half (N=4, 50 %) paraganglioma. SDHB mutation was detected in 1 (12.5 %) patient. Four patients (50 %) had disease progression on follow-up before starting therapy with somatostatin analogues. No objective response was achieved (0 %). However, all patients had disease control ≥ 6 months. Two (33.3 %) of 6 had a ≥ 50 % decrease in metanephrine/ normetanephrine secretion. Median PFS was 21.57 months. (95 % Confidence Interval 14.95–28.19).Conclusion. Based on our findings, we recommend considering somatostatin analogs as a first-line treatment option for patients with indolent disease course and low tumor burden who demonstrate progression during active surveillance. The impact of long-acting somatostatin analogs on catecholamine secretion warrants further investigation in a prospective cohort.
- Open Access
- 30 June 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (3)
The Efficacy of Anthracycline- and Taxane-Containing Neoadjuvant Chemotherapy in Luminal HER2-Negative BRCAmut Breast Cancer
Введение. Герминальные мутации в генах BRCA1/2 встречаются у 5-10 % пациентов с люминальным HER2-негативным раком молочной железы (РМЖ), что ассоциировано с более агрессивным течением и сниженной чувствительностью к гормонотерапии +/- CDKi. Данных об эффективности неоадъювантной химиотерапии (НАХТ) в этой популяции мало, что и стало целью данного исследования. Материалы и методы. В данное ретроспективное исследование включались все пациенты с люминальным (ER > 10 %, ≥ 4 баллов по Allred) HER2-негативным РМЖ II-III стадии с наличием герминальных мутаций в генах BRCA1/2 4 или 5 класса патогенности, получившие антрациклин- и таксансодержащую НАХТ с сентября 2017 по декабрь 2023 гг. Анализировались показатели частоты полного патологического ответа (pCR), предикторы его достижения, а также показатели безрецидивной и общей выживаемости. Результаты. В исследование включена 31 пациентка, из них 14 (45,2 %) имели мутацию в гене BRCA1, 16 (51,6 %) — BRCA2, у одной пациентки (3,2 %) выявлены обе мутации. Средний возраст составил 40,5 лет (27-58), 29 пациенток (93,5 %) были в пременопаузе. Большинство имели местнораспространенную стадию — 23 (74,2 %), cT4 — 18 (58 %), N+ — 26 (83,9 %). В 27 (87,1 %) случаях наблюдалась экспрессия ER ≥ 50 % (6-8 баллов по Allred), у 20 (64,5 %) экспрессия PR ≥ 20 % (4-8 баллов по Allred). Подтип опухоли определен как люминальный В и А в 29 (93,5 %) и 2 (6,5 %) случаях соответственно. Медиана ki67 составила 49,6 % (17-85). Большинство имели опухоль G2 — 23 (74,2 %), G3 — 8 (25,8 %). Частота pCR в общей когорте составила 45,2 % (14/31), в подгруппе мутаций BRCA1 — 64,3 % (n = 9/14) и 31,3 % (n = 5/16) при BRCA2 (p = 0,07). Трехлетняя безрецидивная выживаемость (iDFS) составила 83,3 %, а общая выживаемость (OS) — 94,4 %. Выводы. Таким образом, данное исследование подтверждает высокую чувствительность BRCA-ассоциированного люминального HER2-негативного РМЖ к НАХТ, особенно в подгруппе BRCA1.
- 30 June 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (3)
Open AccessThe Efficacy of Anthracycline- and Taxane-Containing Neoadjuvant Chemotherapy in Luminal HER2-Negative BRCAmut Breast Cancer
Введение. Герминальные мутации в генах BRCA1/2 встречаются у 5-10 % пациентов с люминальным HER2-негативным раком молочной железы (РМЖ), что ассоциировано с более агрессивным течением и сниженной чувствительностью к гормонотерапии +/- CDKi. Данных об эффективности неоадъювантной химиотерапии (НАХТ) в этой популяции мало, что и стало целью данного исследования. Материалы и методы. В данное ретроспективное исследование включались все пациенты с люминальным (ER > 10 %, ≥ 4 баллов по Allred) HER2-негативным РМЖ II-III стадии с наличием герминальных мутаций в генах BRCA1/2 4 или 5 класса патогенности, получившие антрациклин- и таксансодержащую НАХТ с сентября 2017 по декабрь 2023 гг. Анализировались показатели частоты полного патологического ответа (pCR), предикторы его достижения, а также показатели безрецидивной и общей выживаемости. Результаты. В исследование включена 31 пациентка, из них 14 (45,2 %) имели мутацию в гене BRCA1, 16 (51,6 %) — BRCA2, у одной пациентки (3,2 %) выявлены обе мутации. Средний возраст составил 40,5 лет (27-58), 29 пациенток (93,5 %) были в пременопаузе. Большинство имели местнораспространенную стадию — 23 (74,2 %), cT4 — 18 (58 %), N+ — 26 (83,9 %). В 27 (87,1 %) случаях наблюдалась экспрессия ER ≥ 50 % (6-8 баллов по Allred), у 20 (64,5 %) экспрессия PR ≥ 20 % (4-8 баллов по Allred). Подтип опухоли определен как люминальный В и А в 29 (93,5 %) и 2 (6,5 %) случаях соответственно. Медиана ki67 составила 49,6 % (17-85). Большинство имели опухоль G2 — 23 (74,2 %), G3 — 8 (25,8 %). Частота pCR в общей когорте составила 45,2 % (14/31), в подгруппе мутаций BRCA1 — 64,3 % (n = 9/14) и 31,3 % (n = 5/16) при BRCA2 (p = 0,07). Трехлетняя безрецидивная выживаемость (iDFS) составила 83,3 %, а общая выживаемость (OS) — 94,4 %. Выводы. Таким образом, данное исследование подтверждает высокую чувствительность BRCA-ассоциированного люминального HER2-негативного РМЖ к НАХТ, особенно в подгруппе BRCA1.
- 21 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 32,p. 24-28
The role of a «short-term» preoperative endocrine therapy for adjuvant therapy guidance in early HR+ HER2-negative breast cancer
In the absence of widespread access to genomic tests there is an urgent need for additional methods that influence the choice of adjuvant therapy in patients with early luminal Her2-negative subtype of breast cancer (BC). The IMPACT and POETIC trials have shown that Ki67 level decrease up to ≤10% after a “short-term” (2–4 weeks) preoperative endocrine therapy (ET) is a favorable prognostic factor. This test allows some patients to avoid adjuvant chemotherapy associated with immediate and delayed adverse events.Aims of the study. To evaluate the impact of “short-term” preoperative endocrine therapy for guidance of further treatment for patients with primary operable luminal Her2-negative breast cancer stages T1–3 N0–1 M0.Results. The study included 123 patients, 76 (60.8%) received tamoxifen and 47 (37.6%) – aromatase inhibitors (AI). Most patients – 69 (55.2%) were >50 years old, premenopausal – 58 (46.4%), menopausal – 67 (53.6%). The average age was 52 years (30–82). With the initial Ki67 level>10% (N= 107), Ki67 decreased in 24 (22.4%) up to ≤10% after “short-term” ET, and remained >10% in 83 (77.6%). According to the PREDICT calculator, the benefit of adjuvant chemotherapy (AChT) was assessed as high in 35 (28.5%) patients, and 10 of them (27.8%) were able to avoid Ch T. In 86 patients with a relatively low estimated AChT benefit (Conclusions. “Short-term” course of preoperative endocrine therapy is a simple, accessible and reproducible method for personalizing of adjuvant therapy in patients with luminal HER2-negative breast cancer.
- 21 January 2025
- Published by Alfmed LLC in Medical alphabet
- No. 32,p. 24-28
The role of a «short-term» preoperative endocrine therapy for adjuvant therapy guidance in early HR+ HER2-negative breast cancer
In the absence of widespread access to genomic tests there is an urgent need for additional methods that influence the choice of adjuvant therapy in patients with early luminal Her2-negative subtype of breast cancer (BC). The IMPACT and POETIC trials have shown that Ki67 level decrease up to ≤10% after a “short-term” (2–4 weeks) preoperative endocrine therapy (ET) is a favorable prognostic factor. This test allows some patients to avoid adjuvant chemotherapy associated with immediate and delayed adverse events.Aims of the study. To evaluate the impact of “short-term” preoperative endocrine therapy for guidance of further treatment for patients with primary operable luminal Her2-negative breast cancer stages T1–3 N0–1 M0.Results. The study included 123 patients, 76 (60.8%) received tamoxifen and 47 (37.6%) – aromatase inhibitors (AI). Most patients – 69 (55.2%) were >50 years old, premenopausal – 58 (46.4%), menopausal – 67 (53.6%). The average age was 52 years (30–82). With the initial Ki67 level>10% (N= 107), Ki67 decreased in 24 (22.4%) up to ≤10% after “short-term” ET, and remained >10% in 83 (77.6%). According to the PREDICT calculator, the benefit of adjuvant chemotherapy (AChT) was assessed as high in 35 (28.5%) patients, and 10 of them (27.8%) were able to avoid Ch T. In 86 patients with a relatively low estimated AChT benefit (Conclusions. “Short-term” course of preoperative endocrine therapy is a simple, accessible and reproducible method for personalizing of adjuvant therapy in patients with luminal HER2-negative breast cancer.
- Open Access
- 17 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 18-24
Efficacy of chemotherapy and targeted therapy for metastatic pheochromocytoma / paraganglioma: retrospective analysis
Introduction: Pheochromocytoma (PC) and paraganglioma (PG) are rare neuroendocrine tumors derived from adrenal chromaffin cells. The main options of systemic therapy for PC / PG are alkylating agent-based chemotherapy (ChT) and targeted therapy with sunitinib. There are no comparative data on the efficacy of these options, which became the purpose of this study.Materials and methods: This retrospective single-center study included patients over 18 y. o. who received ChT or targeted therapy for the first line treatment for metastatic PC / PG from September 2015 to August 2023.Results: The study included 33 patients (pts) who were divided into two groups — ChT (N = 18, 54.5 %) and targeted therapy (N = 15, 45.5%). In the ChT group, 12 pts (66.7%) received CVD regimen, 6 (33.3%) — temozolomide. In the targeted therapy group, 10 pts (66.7%) received sunitinib, 4 (26.7%) — pazopanib, and 1 (6.7%) — everolimus. Concurrent somatostatin analogues therapy was prescribed in 12 (66.7%) and 10 (66.7%) pts in the ChT and targeted therapy groups, respectively. Both groups were comparable by all main characteristics. Objective response was achieved in 11.11 % (N = 2) and 6.67 % (N = 1) [p=0.99], disease control > 6 months — 61.11 % and 60% (p = 0.99), biochemical response — 36.36% and 30% (p = 0.9) in the ChT and targeted therapy groups, respectively. Median PFS was 12.7 (2.9-22.3) in the ChT versus 12.9 months (2.3-26.5) in the targeted therapy group (p = 0.55). Median overall survival was not reached in both groups.Discussion: According to comparable efficacy of both treatment options and the indolent course of PC / PG, most patients do not require ChT in the 1st line of treatment. While choosing the 1st line therapy it is necessary firstly to take into account the safety profile of the drugs.
- 17 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 18-24
Open AccessEfficacy of chemotherapy and targeted therapy for metastatic pheochromocytoma / paraganglioma: retrospective analysis
Introduction: Pheochromocytoma (PC) and paraganglioma (PG) are rare neuroendocrine tumors derived from adrenal chromaffin cells. The main options of systemic therapy for PC / PG are alkylating agent-based chemotherapy (ChT) and targeted therapy with sunitinib. There are no comparative data on the efficacy of these options, which became the purpose of this study.Materials and methods: This retrospective single-center study included patients over 18 y. o. who received ChT or targeted therapy for the first line treatment for metastatic PC / PG from September 2015 to August 2023.Results: The study included 33 patients (pts) who were divided into two groups — ChT (N = 18, 54.5 %) and targeted therapy (N = 15, 45.5%). In the ChT group, 12 pts (66.7%) received CVD regimen, 6 (33.3%) — temozolomide. In the targeted therapy group, 10 pts (66.7%) received sunitinib, 4 (26.7%) — pazopanib, and 1 (6.7%) — everolimus. Concurrent somatostatin analogues therapy was prescribed in 12 (66.7%) and 10 (66.7%) pts in the ChT and targeted therapy groups, respectively. Both groups were comparable by all main characteristics. Objective response was achieved in 11.11 % (N = 2) and 6.67 % (N = 1) [p=0.99], disease control > 6 months — 61.11 % and 60% (p = 0.99), biochemical response — 36.36% and 30% (p = 0.9) in the ChT and targeted therapy groups, respectively. Median PFS was 12.7 (2.9-22.3) in the ChT versus 12.9 months (2.3-26.5) in the targeted therapy group (p = 0.55). Median overall survival was not reached in both groups.Discussion: According to comparable efficacy of both treatment options and the indolent course of PC / PG, most patients do not require ChT in the 1st line of treatment. While choosing the 1st line therapy it is necessary firstly to take into account the safety profile of the drugs.